获国自然面上项目、青年项目，国家重点研发计划，上海市面上项目等支持。

代表论文(#Co-first author, *Co-corresponding author)：

2026年：

1.     Du, Y.,He, M., Xu, Y.X., Tian, T., Zhou, Y., Zhang, Y., Fu, H., Li, J., Lv, L.*, and Xu, Y.*(2026). AARS1-mediatedlactylation of STAT1 drives immune evasion. Cell Rep 45,117094.

2.     Cui,Z., Li, H., Liang, X., Zhao, X., Xu, K., Lu, Y., Zhang, Y., Li, X., Wu, S.,Wang, Z.*, Lv, L.*, and Xu, Y.*(2026). AKT1 phosphorylates PRMT7 to promote GLUD1 methylation and gastriccancer progression. Cell Death Dis 17, 363.

2025年：

1.     Zhang,J., Tian, T., Li, X., Xu, K., Lu, Y., Li, X., Zhao, X., Cui, Z., Wang, Z.,Zhou, Y., Xu, Y.X., Li, H., Zhang, Y., Du, Y., Lv, L., and Xu, Y.* (2025). p53 inhibits OTUD5 transcription to promoteGPX4 degradation and induce ferroptosis in gastric cancer. Clin Transl Med 15,e70271. (ESI Highly cited paper)

2.     Li,H., Zhang, X., Liang, X., Li, S., Cui, Z., Zhao, X., Wang, K., Zha, B., Ma, H.*,Xu, M.*, Lv, L.*, and Xu, Y.*(2025). HNF4α-TET2-FBP1 axis contributes to gluconeogenesis and type 2diabetes. Elife 13, RP103663

3.     Dai,Y., Li, H., Fan, S., Wang, K., Cui, Z., Zhao, X., Sun, X., Lin, M., Li, J.,Gao, Y., Tian, Z., Yang, H.*, Zha, B.*, Lv, L.*, and Xu, Y.* (2025). Dimethyl fumarate promotes the degradationof HNF1B and suppresses the progression of clear cell renal cell carcinoma. CellDeath Dis 16, 71.

4.     Gao,Y., Fan, S., Sun, X., Li, J., Dai, Y., Li, H.C., Ma, H.*, Xu, Y.*, and Lv, L.* (2025). Oncometabolite fumaratefacilitates PD-L1 expression and immune evasion in clear cell renal cellcarcinoma. Cell Death Dis 16, 432.

5.     He,J., Lin, M., Teng, F., Sun, X., Tian, Z., Li, J., Ma, Y., Dai, Y., Gao, Y., Li,H., Tian, T., Xu, K.*, Li, X.*, Lv, L.*, and Xu, Y.* (2025). TET2 orchestrates YAP signaling topotentiate targetable vulnerability in hepatocellular carcinoma. CellDeath Dis 16, 438.

6.     Yin,X., Wu, J., Xu, M., Tian, T., Zhu, L., Wang, J., Dai, X., Yang, X., Qian, J.,Wang, W., Zhu, L., Zhao, Z., Xu, K., Xu,Y.*, Li, X.*, and Hu, Z.* (2025). Immune-related deubiquitylationspectrum of microsatellite stability colorectal cancer reveals USP7 as apotential immunotherapeutic target. Mol Cancer 25, 44.

2024年：

1.     Dong,W., Lin, M., Zhang, R., Sun, X., Li, H., Liu, T.*, Xu, Y.*, and Lv, L.* (2024). D-mannose targets PD-1 tolysosomal degradation and enhances T cell-mediated anti-tumor immunity.Cancer Lett 1, 216883.

2023年：

1.     Lin,M., He, J., Zhang, X., Sun, X., Dong, W., Zhang, R., Xu, Y.*, and Lv, L.* (2023). Targeting fibrinogen-likeprotein 1 enhances immunotherapy in hepatocellular carcinoma. JClin Invest 133. （Previewedby JCI, Editor’s picks）

2.     Tian,T., Xie, X., Yi, W., Zhou, Y., Xu, Y., Wang, Z., Zhang, J., Lin, M., Zhang, R.,Lv, Z., Li, X., Lv, L.*, Xu, Y.*.(2023). FBXO38 mediates FGL1 ubiquitination and degradation to enhance cancerimmunity and suppress inflammation. Cell Rep 42,113362.

3.     Sun,X., Dai, Y., He, J., Li, H., Yang, X., Dong, W., Xie, X., Wang, M., Xu, Y.*, and Lv, L.* (2023).D-mannose induces TFE3-dependent lysosomal degradation of EGFR and inhibits theprogression of NSCLC. Oncogene 42, 3503-3513.

4.     He,J., Lin, M., Zhang, X., Zhang, R., Tian, T., Zhou, Y., Dong, W., Yang, Y., Sun,X., Dai, Y., Xu, Y., Zhang, Z., Xu, M., Lei, Q.Y., Xu, Y.*, and Lv, L.* (2023). TET2 is required to suppressmTORC1 signaling through urea cycle with therapeutic potential. CellDiscovery 9.

2022年：

1.     Zhang,R., Yang, Y., Dong, W., Lin, M., He, J., Zhang, X., Tian, T., Yang, Y., Chen,K., Lei, Q.Y., Zhang, S.*, Xu, Y.*,and Lv, L.* (2022). D-mannose facilitates immunotherapy and radiotherapy oftriple-negative breast cancer via degradation of PD-L1. Proc Natl Acad Sci U S A119. (ESI Highly cited paper)

2.     Zhang,X., Li, S., He, J., Jin, Y., Zhang, R., Dong, W., Lin, M., Yang, Y., Tian, T.,Zhou, Y., Xu, Y., Lei, Q.Y., Zhang, J., Zhang, Q., Xu, Y.*, and Lv, L.* (2022). TET2 Suppresses VHLDeficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling. CancerRes 82, 2097-2109.

3.     Yi,W., Qiao, T., Yang, Z., Hu, L., Sun, M., Fan, H., Xu, Y.*, and Lv, Z.* (2022). The regulation role anddiagnostic value of fibrinogen-like protein 1 revealed by pan-cancer analysis. MaterToday Bio 17, 100470

2021年之前：

1.     Chen,L.L., Smith, M.D., Lv, L., Nakagawa, T., Li, Z., Sun, S.C., Brown, N.G., Xiong,Y.*, and Xu, Y.* (2020).USP15 suppresses tumor immunity via deubiquitylation and inactivation of TET2. SciAdv 6.

2.     Xu, Y., Lv, L., Liu, Y., Smith, M.D., Li, W.C., Tan, X.M.,Cheng, M., Li, Z., Bovino, M., Aube, J., Xiong, Y.* (2019). Tumor suppressorTET2 promotes cancer immunity and immunotherapy efficacy. J Clin Invest 129,4316-4331.

3.     Lv,L.#, Wang, Q.#, Xu, Y.#,Tsao, L.C.#, Nakagawa, T., Guo, H., Su, L.*, and Xiong, Y.* (2018). Vpr TargetsTET2 for Degradation by CRL4(VprBP) E3 Ligase to Sustain IL-6 Expression andEnhance HIV-1 Replication. Mol Cell 70, 961-970 e965.

4.     Murphy,C.M.#, Xu, Y.#, Li, F.#, Nio,K., Reszka-Blanco, N., Li, X., Wu, Y., Yu, Y., Xiong, Y.*, and Su, L.* (2016).Hepatitis B Virus X Protein Promotes Degradation of SMC5/6 to Enhance HBVReplication. Cell Rep 16, 2846-2854.

5.     Xu, Y., Li, F., Lv, L., Li, T., Zhou, X., Deng, C.X., Guan,K.L., Lei, Q.Y.*, and Xiong, Y.* (2014). Oxidative stress activates SIRT2 todeacetylate and stimulate phosphoglycerate mutase. Cancer Res 74, 3630-3642.

6.     Lv,L.#, Xu, Y.#, Zhao, D., Li,F.L., Wang, W., Sasaki, N., Jiang, Y., Zhou, X., Li, T.T., Guan, K.L., Lei,Q.Y.*, and Xiong, Y.* (2013). Mitogenic and oncogenic stimulation of K433acetylation promotes PKM2 protein kinase activity and nuclear localization. MolCell 52, 340-352. (Cover Story,Highlighted by Nature Reviews Cancer and Cancer Discovery)